Ben-Noon Alon 4
Research Summary
AI-generated summary
NeuroSense (NRSN) CEO Ben‑Noon Alon Buys 250,000 Shares
What Happened
Ben‑Noon Alon, CEO of NeuroSense Therapeutics Ltd. (NRSN), acquired 250,000 ordinary shares on June 16, 2026, at $0.80 per share, for a total purchase price of $200,000. The shares were bought in a private placement rather than an open‑market trade.
Key Details
- Transaction date: 2026-06-16; Form 4 filed: 2026-06-17 (timely filing).
- Transaction type/code: Purchase (P).
- Shares acquired: 250,000 at $0.80 each; total cost $200,000.
- Shares owned after transaction: Not disclosed in the filing provided.
- Footnote: Acquisition pursuant to a Securities Purchase Agreement dated April 28, 2026, in a private placement exempt from registration under Section 4(a)(2) of the Securities Act (per filing footnote).
- No indication of a 10b5‑1 plan, gift, option exercise, or tax withholding in this filing.
Context
This was a private placement purchase (negotiated under an SPA and exempt from registration), not an open‑market buy. Purchases by insiders are often watched by investors as potentially more informative than sales, but the filing itself does not state the insider’s motivation or any broader financing context.